249 related articles for article (PubMed ID: 31010847)
1. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Scheffold A; Jebaraj BMC; Tausch E; Bloehdorn J; Ghia P; Yahiaoui A; Dolnik A; Blätte TJ; Bullinger L; Dheenadayalan RP; Li L; Schneider C; Chen SS; Chiorazzi N; Dietrich S; Seiffert M; Tannheimer S; Döhner H; Mertens D; Stilgenbauer S
Blood; 2019 Aug; 134(6):534-547. PubMed ID: 31010847
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia.
Yaktapour N; Übelhart R; Schüler J; Aumann K; Dierks C; Burger M; Pfeifer D; Jumaa H; Veelken H; Brummer T; Zirlik K
Blood; 2013 Aug; 122(9):1621-33. PubMed ID: 23863897
[TBL] [Abstract][Full Text] [Related]
3. Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
Leroy C; Ramos P; Cornille K; Bonenfant D; Fritsch C; Voshol H; Bentires-Alj M
Breast Cancer Res; 2016 Apr; 18(1):41. PubMed ID: 27048245
[TBL] [Abstract][Full Text] [Related]
4. The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.
Herman SE; Lapalombella R; Gordon AL; Ramanunni A; Blum KA; Jones J; Zhang X; Lannutti BJ; Puri KD; Muthusamy N; Byrd JC; Johnson AJ
Blood; 2011 Apr; 117(16):4323-7. PubMed ID: 21378270
[TBL] [Abstract][Full Text] [Related]
5. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
Murali I; Kasar S; Naeem A; Tyekucheva S; Khalsa JK; Thrash EM; Itchaki G; Livitz D; Leshchiner I; Dong S; Fernandes SM; Getz G; Johnson A; Brown JR
Blood; 2021 Jul; 138(1):44-56. PubMed ID: 33684943
[TBL] [Abstract][Full Text] [Related]
6. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Brown JR
Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
[TBL] [Abstract][Full Text] [Related]
7. Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Aydin E; Faehling S; Saleh M; Llaó Cid L; Seiffert M; Roessner PM
Front Immunol; 2020; 11():595818. PubMed ID: 33552053
[TBL] [Abstract][Full Text] [Related]
8. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J
Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237
[TBL] [Abstract][Full Text] [Related]
9. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
11. The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
Rohrbacher L; Brauchle B; Ogrinc Wagner A; von Bergwelt-Baildon M; Bücklein VL; Subklewe M
Front Immunol; 2021; 12():608625. PubMed ID: 33790890
[TBL] [Abstract][Full Text] [Related]
12. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Krause G; Hassenrück F; Hallek M
Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.
Herman SE; Johnson AJ
Clin Cancer Res; 2012 Aug; 18(15):4013-8. PubMed ID: 22711705
[TBL] [Abstract][Full Text] [Related]
14. Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474.
Isoyama S; Kajiwara G; Tamaki N; Okamura M; Yoshimi H; Nakamura N; Kawamura K; Nishimura Y; Namatame N; Yamori T; Dan S
Cancer Sci; 2015 Feb; 106(2):171-8. PubMed ID: 25483727
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Morabito F; Gentile M; Seymour JF; Polliack A
Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
[TBL] [Abstract][Full Text] [Related]
16. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
17. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
18. Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.
de Lint K; Poell JB; Soueidan H; Jastrzebski K; Vidal Rodriguez J; Lieftink C; Wessels LF; Beijersbergen RL
Mol Cancer Ther; 2016 Jul; 15(7):1545-56. PubMed ID: 27196766
[TBL] [Abstract][Full Text] [Related]
19. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
[TBL] [Abstract][Full Text] [Related]
20. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]